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The microenvironment of the primary as well as the metastatic tumor sites can determine the ability for
a disseminated tumor to progress. In this issue of Cancer Cell, Calon and colleagues find that systemic
TGF-b can facilitate colon cancer metastatic engraftment and expansion.Preventing the metastatic progression of
tumors is a prevailing issue in cancer
biology. In liquid tumors, like multiple
myeloma, which colonizes the bone, we
can imagine the cancer cells have pre-
existing equipment required to survive
and thrive in the bone microenvironment.
For ovarian serous carcinoma dis-
semination and expansion within the
peritoneal cavity, cell autonomous mech-
anisms of tumor proliferation, epithelial-
to-mesenchymal transdifferentiation, and
anti-apoptotic signaling may be predomi-
nant requirements for metastasis. How-
ever, the non-random metastatic tropism
of solid tumors, such as that of the breast,
colon, and prostate, often need to adapt
to more than one distant site, including
lymph nodes, bone, and soft tissue. In
these examples, tumor size at the primary
site and the number of circulating tumor
cells are relatively less significant determi-
nants of adaptation at the secondary site.
The extensive global sequencing efforts
of the primary tumor epithelia have not
helped to predict colon cancer metastatic
potential (Jones et al., 2008). In contrast,
profiling the microenvironment of the pri-
mary tumor seems to bepredictive for liver
and prostate cancer metastatic progres-
sion (Blum et al., 2008; Budhu et al.,
2006). In this issue of Cancer Cell, Calon
et al. (2012) report that measuring recipro-
cating signals by the tumor and host are
likely going to be more predictive of colon
cancer growth at the metastatic site.
Specifically, the authors found that ele-
vated levels of transforming growth
factor-beta (TGF-b) expression was a
superior predictor of metastatic growth
of colon cancer rather than pathologic
staging. They present a study addressingthe apparent paradox characterized by
high TGF-b levels in the tumor and muta-
tional inactivation of TGF-b signaling
observed in colon cancer epithelia. As
such, the elevated TGF-b would be
affecting the cells of the host, in particular,
endothelia and fibroblasts, at the distant
metastatic site. Calon et al. (2012) suggest
that a stromal TGF-b response, involving
IL-11, potentiates colon cancer engraft-
ment and growth at liver and lung meta-
static sites. The immune regulatory effects
of TGF-b could not be specifically exam-
ined as the observations were made in
immune-compromised xenograft mouse
models. However, the work suggests a
novel mechanism of colon cancer meta-
static progression following the initial
steps of tumor cell dissemination.
Multiple mechanisms of metastatic
progression are possible. One such pos-
sibility is that tumor cells possessing
stem-like features may have a growth
advantage in a secondary site; their plu-
ripotent potential could presumably facili-
tate adaptation to a new environment
(Figure 1A). A tumor cell cannot evolve
to adapt to an environment to which it
has not been exposed. In this case, the
success of the metastasis is reliant on
the plasticity of the stem-like tumor cell.
A recent report suggested that expression
of the extracellular matrix component
periostin in mammary tumors can support
stem-like features to favor metastatic pro-
gression (Malanchi et al., 2012). In the
process of prostate cancer and stromal
coevolution in the primary tumor site,
paracrine cytokines expressed by pros-
tatic fibroblasts that lose TGF-b respon-
siveness alter the interactions of tumor
epithelia, with its matrix enabling signifi-Cancer Cell 22, Ncant expansion in secondary bone tissue
(Li et al., 2012). Another recent report
supports the idea that specific changes
in the matrix and its integrin interaction
with primary lung tumor cells are critical
determinants of metastatic progression
(Reticker-Flynn et al., 2012). Figure 1B
illustrates that an alternative means of
successful metastatic progression can
be a result of a disseminated tumor cell
having the ability to survive in the sec-
ondary site until it can express factors
that enable it to thrive (Stoecklein et al.,
2008). The secondary tissue microenvi-
ronment can reciprocally respond to the
disseminated tumor cell, such that a
collaborative effort enables metastatic
progression. Tumor dormancy, which is
associated with micrometastases that
are not visibly progressing, can involve
the coevolutionary process at the meta-
static site, which includes cell autono-
mous changes as well as those of the
host vasculature and immune system.
It has been clear for some time that
TGF-b mediates processes associated
with tumor cell extravasation in terms
of increased motility and cell survival.
However, these cell-autonomous TGF-b
activities cannot be attributed to elevated
metastatic potential, because TGF-b
signaling is increasingly found to be
impaired or completely absent in multiple
cancer types, including colon cancer
epithelia. Figure 1C illustrates changes
that can occur in the primary and meta-
static tumor microenvironment as a re-
sult of elevated systemic TGF-b. These
changesmay normalize themicroenviron-
ment of the two sites such that the meta-
static niche is primed for tumor growth, as
suggested in the study by Calon et al.ovember 13, 2012 ª2012 Elsevier Inc. 563
Figure 1. Scenarios for Metastatic Expansion
There are multiple possible mechanisms for metastatic progression. It is assumed that the rate limiting
steps of metastasis do not necessarily involve the processes of tumor cell dissemination, but rather
compatibility of tumor cells with their metastatic site.
(A) A primary tumor cell can acquire traits within the primary tumor that enable its progression in the meta-
static site.
(B) Alternatively, the disseminated tumor cells that lodge in the metastatic site can lie ‘dormant’ until the
new microenvironment potentiates the acquisition of traits that enable tumor progression.
(C) The work by Calon et al. (2012) suggests that elevated TGF-b and its downstream products induce
changes in the microenvironment of the primary tumor and the metastatic site to facilitate metastatic
progression. There are other possibilities mediating metastatic progression including variations and com-
binations of these three scenarios. The role of the immune system is not accounted for in this assessment.
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system in the development of a pre-meta-
static niche has been described (Kaplan
et al., 2005). However, the detection of
TGF-b in circulation in colon cancer meta-
static progression in patients supports the
role of tumor-derived cytokines in the
primary site having long range effects in
altering the microenvironment of the
metastatic site (Calon et al., 2012). The
role of TGF-b in altering the microenvi-
ronment of the primary and metastatic
sites can be therapeutically leveraged.
For example, TGF-b blockade increases
chemotherapeutic penetration into tu-
mors by causing perivascular cell activa-
tion, leading to increased tumor perfusion
and reduced extracellular matrix forma-
tion (Liu et al., 2012).
Translational opportunities for the
application of these results are dependent
on further understanding of the host
response to TGF-b signaling. The inhibi-564 Cancer Cell 22, November 13, 2012 ª20tion of TGF-b signaling at the level of
the ligand, receptor-ligand complex, and
intracellular signaling molecules are being
studied. However, the targeting of down-
stream paracrine factors, initially thought
to be a fools-game of chasing the numer-
ous TGF-b responsive genes, is starting
to come down to fewer examples of
viable candidates to support greater
tumor specificity. Nevertheless, there is
an even greater need to understand the
metastatic site in order to appropriately
determine the TGF-b induced factor(s).
Metastatic tropism is reliant on the
dynamics of the tumor cell as it attempts
to convert its microenvironment to its
advantage (Figure 1). Thus, to time the
therapeutic window for pharmacological
intervention of a metastatic mechanism
would be challenging. However, address-
ing metastasis methods collectively used
by heterogeneous tumors may require
a multipronged approach that would12 Elsevier Inc.include targeting the microenvironment
at both primary and metastatic sites
through a cell type-directed manner.REFERENCES
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